Skip to content
value.today
Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

HBIO
$38 Mmarket cap on Oct 26, 2026-82.2% since Jan 2024
Compare
World rank
#22,291
Revenue
$87 M
For year ending December-2025
Net income
$-57 M
-65.5% margin
SEC filing
Employees
—

Harvard Bioscience, Inc. in brief

Harvard Bioscience, Inc. is a listed company in the Medical Instruments industry, based in Holliston, Massachusetts, USA. It was founded in 1901. Its market value was $38 M on 26 October 2026, which makes it the 22,291st largest listed company in the world and the 3,975th largest in the USA on this site. In the year to December 2025 it had sales of $87 M and a net loss of $57 M. John D. Duke is its chief executive. Its largest product and service lines by sales in 2025 were Instruments, Equipment, Software, and Accessories (90%) and Service, Maintenance, and Warranty Contracts (10%). By market, the largest shares of its 2025 sales came from USA (45%), EMEA (31%) and China (13%). Its shares trade under the symbol HBIO (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Harvard Bioscience, Inc.

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Harvard Bioscience, Inc. timeline

3 events, 1901–2000
  1. 1901
  2. 🏁
    · approximate
    Founded
  3. 2000
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 🔔
    · approximate
    Initial public offering on Nasdaq as HBIO

Events of Harvard Bioscience, Inc. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$73 M$147 M$220 M$294 M2020202120222023202420252026

World rank over time

▼ down 4,162 places since 2020
2020-01-01: #18163#18,16320202021-01-01: #16271#16,27120212022-01-07: #17275#17,27520222022-12-25: #20968#20,96820222024-01-05: #17587#17,58720242026-03-08: #11843#11,84320262026-08-01: #20836#20,83620262026-10-26: #22325#22,3252026

Rank in USA: #3,606 (Jan 2020) · #3,370 (Jan 2021) · #3,565 (Jan 2022) · #4,161 (Dec 2022) · #3,206 (Jan 2024) · #2,286 (Mar 2026) · #3,871 (Aug 2026) · #3,978 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.4×
Price / book
2.7×
Free cash flow yield
14.5%
Net margin (TTM)
-13.2%
Operating margin
-56.1%
Return on equity
-85.9%
Liabilities / assets
82.9%
Net debt
$27M
Revenue growth
-8.1%
R&D / revenue
10.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $121M, net income $-3M$121MFY18Fiscal year ending Dec 2019: revenue $116M, net income $-5M$116MFY19Fiscal year ending Dec 2020: revenue $102M, net income $-8M$102MFY20Fiscal year ending Dec 2021: revenue $119M, net income $-0M$119MFY21Fiscal year ending Dec 2022: revenue $113M, net income $-10M$113MFY22Fiscal year ending Dec 2023: revenue $112M, net income $-3M$112MFY23Fiscal year ending Dec 2024: revenue $94M, net income $-12M$94MFY24Fiscal year ending Dec 2025: revenue $87M, net income $-57M$87MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$87M-8.1%$-49M$-57M-65.5%
Dec 2024$94M-16.1%$-6M$-12M-13.2%
Dec 2023$112M-1.0%$2M$-3M-3.0%
Dec 2022$113M-4.7%$-7M$-10M-8.4%
Dec 2021$119M+16.5%$2M$-0M-0.2%
Dec 2020$102M-12.1%$0M$-8M-7.6%
Dec 2019$116M-3.8%$0M$-5M-4.0%
Dec 2018$121M—$1M$-3M-2.4%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$7M$1M$5M$-1.28—
Dec 2024$1M$3M$-1M$-0.28—
Dec 2023$14M$2M$12M$-0.08—
Dec 2022$1M$2M$-0M$-0.23—
Dec 2021$1M$1M$0M$-0.01—
Dec 2020$9M$1M$8M$-0.20—
Dec 2019$8M$1M$7M$-0.12—
Dec 2018$3M$1M$2M$-0.08—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$89M
Net income, trailing 12 months
$-12M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $25M, net income $0M$25MDec ’24Three months to Mar 2025: revenue $22M, net income $-50M$22MMar ’25Three months to Jun 2025: revenue $20M, net income $-2M$20MJun ’25Three months to Sep 2025: revenue $21M, net income $-1M$21MSep ’25Three months to Dec 2025 (from the annual report): revenue $24M, net income $-3M$24MDec ’25Three months to Mar 2026: revenue $21M, net income $-3M$21MMar ’26Three months to Jun 2026: revenue $23M, net income $-3M$23MJun ’26Three months to Sep 2026: revenue $22M, net income $-3M$22MSep ’26

Latest quarter to Sep 2026: revenue $22M (+7.8% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Harvard Bioscience, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$87 M
Operating income
$-49 M
Net income
$-57 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$80 M
Total liabilities
$66 M
Total equity
$14 M

As of December-2025

Top 30 institutional investors in Harvard Bioscience, Inc.#

As of Sep 30, 2026
30 institutions held 1.4 M shares (about 30.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 26.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Harvard Bioscience, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Weber Capital Management LLC /adv299,816-11,045 (-3.55%)6.56%$2 MOct 19, 2026
2Acadian Asset Management LLC179,6140 (0.00%)3.93%$1 MNov 9, 2026
3Vanguard Capital Management LLC172,065+2,440 (+1.44%)3.76%$1 MNov 13, 2026
4Mink Brook Asset Management LLC124,199+90,830 (+272.20%)2.72%$1 MNov 13, 2026
5Corsair Capital Management, L.P.122,8100 (0.00%)2.69%$1 MNov 16, 2026
6Renaissance Technologies LLC94,327-5,000 (-5.03%)2.06%$1 MNov 12, 2026
7Two Sigma Investments, LP85,535-29,010 (-25.33%)1.87%$1 MNov 16, 2026
8BlackRock, Inc.61,893+59 (+0.10%)1.35%$0 MNov 13, 2026
9Geode Capital Management, LLC46,753-802 (-1.69%)1.02%$0 MNov 6, 2026
10Vanguard Fiduciary Trust Co27,7300 (0.00%)0.61%$0 MNov 13, 2026
11Millennium Management LLC27,060-5,560 (-17.04%)0.59%$0 MNov 16, 2026
12Essex Investment Management Co LLC26,9730 (0.00%)0.59%$0 MOct 19, 2026
13Citadel Advisors LLC24,811+11,560 (+87.24%)0.54%$0 MNov 16, 2026
14Williams & Novak Wealth Management, LLC16,555-4,394 (-20.97%)0.36%$0 MOct 9, 2026
15RBF Capital, LLC16,0000 (0.00%)0.35%$0 MNov 13, 2026
16State Street Corp14,9320 (0.00%)0.33%$0 MNov 12, 2026
17UBS Group AG12,404-5,177 (-29.45%)0.27%$0 MNov 10, 2026
18Gsa Capital Partners LLP11,499New0.25%$0 MNov 16, 2026
19Dimensional Fund Advisors LP10,753New0.24%$0 MNov 4, 2026
20Bank of New York Mellon Corp10,2300 (0.00%)0.22%$0 MNov 5, 2026
21Morgan Stanley9,909+8,282 (+509.04%)0.22%$0 MNov 13, 2026
22FMR LLC3,086-93 (-2.93%)0.07%$0 MNov 10, 2026
23Vanguard Global Advisers, LLC1,2210 (0.00%)0.03%$0 MNov 13, 2026
24SBI Securities Co., Ltd.8660 (0.00%)0.02%$0 MOct 22, 2026
25Brown Shipley& Co Ltd4780 (0.00%)0.01%$0 MOct 9, 2026
Show all 30: investors 26 to 30
Institutional investors 26 to 30 in Harvard Bioscience, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Tower Research Capital LLC (TRC)451-129 (-22.24%)0.01%$0 MNov 16, 2026
27Nisa Investment Advisors, LLC2280 (0.00%)0.01%$0 MOct 20, 2026
28Royal Bank Of Canada129+114 (+760.00%)0.00%$0 MNov 16, 2026
29BNP Paribas Financial Markets660 (0.00%)0.00%$0 MNov 12, 2026
30Jpmorgan Chase & Co32-163 (-83.59%)0.00%$0 MNov 12, 2026

Mutual funds holding Harvard Bioscience, Inc.#

18 funds hold shares worth $1 M (about 5.1% of the company). Since their previous reports 9 added shares and 3 sold, buying $0 M net.
Mutual funds holding Harvard Bioscience, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.123,470$1 M2.7%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.42,043$0 M0.92%<0.01%+5.5%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC27,769$0 M0.61%<0.01%+24%May 31, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC13,380$0 M0.29%0.07%—Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,017$0 M0.15%<0.01%−0.0%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,946$0 M0.13%<0.01%+7.0%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,112$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC2,936$0 M0.06%<0.01%−0.0%May 31, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP1,902$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP1,366$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP1,229$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP1,029$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP928$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC683$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation601$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP258$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC30$0 M<0.01%<0.01%−2.3%May 29, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP24$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 18 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Harvard Bioscience, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$202 K
5 purchases, 4 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$202 K
open market only
Insiders on file
29
since
$202 K$0Jun 2024: bought $91 K (2 trades), sold $0 (0 trades)Jun 24Mar 2026: bought $202 K (5 trades), sold $0 (0 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Harvard Bioscience, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Katherine A. EadeDirectorGrant or award+16,556——58,669Form 4
filed Robert E. GagnonDirectorGrant or award+16,556——27,556Form 4
filed Seth Benjamin BensonDirectorGrant or award+16,556——27,556Form 4
filed William SniderDirectorGrant or award+16,556——48,556Form 4
filed Stephen J. DenelskyDirectorGrant or award+16,556——37,556Form 4
filed Mark T. FrostChief Financial OfficerGrant or award+30,000——47,500Form 4
filed John D. DukeChief Executive Officer, DirectorGrant or award+75,000——180,000Form 4
filed Stephen J. DenelskyDirectorBuy+10,000$4.870$49 K21,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Harvard Bioscience, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
66,461
3.5 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 10-for-1 split

Trading halts

  • 2026-03-13 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 788 shares at $8.23
  • : 837 shares at $6.37
  • : 98 shares at $6.05
  • : 359 shares at $5.40
  • : 1,951 shares at $6.78

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Harvard Bioscience, Inc. scorecard#

Passes 6 of the 23 checks that could be worked out: strongest in valuation (3 of 6), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation3 of 6
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.7×Price to book 2.7× against Medical Instruments's median of 3.9×.
    • ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Medical Instruments's median of 3.0×.
    • ✓Free cash flow yield above 5%14.5%Free cash flow is 14.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • ✗The price assumes slower growth than the last three years'0.7%The price assumes 0.7% a year for ten years; revenue grew -8.6% a year over the last three.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-8.1%Revenue down 8.1% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-8.6%-8.6% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-8.6%-8.6% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year-1.28 vs -0.28Diluted EPS -1.28 in fiscal 2025 against -0.28 the year before (report's currency).
    • ✗Net income higher than five years earlier-$57 M-$57 M in fiscal 2025 against -$8 M in 2020.
    • ✗Revenue rose in at least four of the last five years1 of 5Revenue rose in 1 of the five years to fiscal 2025.
  • Profitability0 of 5
    • ✗Profitable in the newest year-$57 MNet income -$57 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-56.1%-56.1% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%-147.1%-147.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-56.1%-56.1% in fiscal 2025 against -6.1% in 2022.
  • Financial health2 of 5
    • ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.20 at the end of fiscal 2025.
    • ✗Debt below equity2.6×Debt to equity 2.61 at the end of fiscal 2025.
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-37.4×Operating income -37.4 times interest in fiscal 2025.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-3.94Z-score -3.94 (distress zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year2.0%Diluted shares up 2.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Harvard Bioscience, Inc.'s statements, beside the median of Medical Instruments.

Harvard Bioscience, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-56.1%7.2%
Net margin-65.5%3.8%
Return on equity-147.1%3.5%
Revenue growth, 3 years a year-8.6%5.0%
Revenue growth-8.1%8.9%
Debt to equity2.61×0.46×

5of 9on the Piotroski tests of financial strength

  • Revenue fell 8.1% against the year before.
  • Net loss of $57 million, the 11th loss-making year in a row.
  • Operating income covers the interest bill only -37.4 times.
  • Goodwill and intangibles ($17 million) exceed shareholders' equity ($14 million).

Harvard Bioscience, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Harvard Bioscience, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue879411211311910211612177r105
Cost of revenue373946535144525838r56
Gross profit505566616858646339r48
Research and development8.8101212118.711115.65.4
Selling and marketing192224r252520232415r20
General and administrative182123r242424232118r21
Operating expenses986164686658646240r51
Operating income−49−6.21.9−6.92.10.20.41.0−0.6r−3.0
Interest expense and finance costs3.63.2—————5.40.70.6r
Other non-operating income (expense)−8.8−5.5−4.5−2.2−2.2−7.5−5.9−9.0−2.0r−0.1
Income before tax−57−12−2.6−9.2−0.1−7.3−5.5−8.0−2.6r−3.1
Income tax−0.70.70.90.30.10.5−0.8−3.7−0.6r1.2
Income from continuing operations——————−4.7−4.3−2.0—
Income from discontinued operations———————1.41.2—
Net income attributable to shareholders−57−12−3.4−9.5−0.3−7.8−4.7−2.9−0.9−4.3
Earnings per share, basic-1.28-0.28-0.08-0.23-0.01-0.20-0.12-0.08-0.02-0.13
Earnings per share, diluted-1.28-0.28-0.08-0.23-0.01-0.20-0.12-0.08-0.02-0.13
Shares, weighted average (basic)444442414039r38363534
Shares, weighted average (diluted)444442414039r38363534
Balance sheet
Cash and cash equivalents8.64.14.34.57.88.38.38.25.7r5.6
Receivables161516172218212113r16
Inventory212325262822222517r20
Other current assets2.82.93.93.54.33.42.53.13.7r4.2
Current assets48454951625254584845
Property, plant and equipment4.85.14.03.43.44.04.85.93.7r4.3
Right-of-use (leased) assets7.26.14.85.86.97.88.50——
Goodwill9.65657565859575736r38
Other intangible assets7.611162127333846r10r17
Total assets80127137145162156165169109108
Accounts payable3.74.85.66.44.96.05.37.44.4r6.2
Debt due within a year037r6.14.13.52.03.22.4——
Current liabilities2255272325212525r1415
Long-term debt360314345464755r9.011
Lease liabilities (non-current)6.96.44.85.36.57.58.20——
Total liabilities66636473798083862836
Retained earnings−215−158−146−142−133−132−125−120−117−116
Shareholders' equity1463r7372837782838172
Total liabilities and equity80127137145162156165169109108
Shares outstanding4.5r444342413938373535r
Cash-flow statement
Share-based compensation1.94.35.04.44.23.63.03.03.53.5
Cash from operating activities6.71.4141.21.39.38.02.91.15.4
Capital expenditure−1.3−2.6−1.8−1.6−1.2−1.2−1.2−1.0−0.9—
Intangible assets bought−0.6−0.6−0.50−0.2−0.3————
Acquisitions, net of cash acquired———————−6900
Cash from investing activities−1.9−1.3−1.8−1.6−1.3−1.4−0.2−54−0.9−0.1
Debt issued400————————
Debt repaid−25−6.0−4.1−3.2−2.0r−67−12−20−4.7−9.1
Shares issued———————4.60.20.2
Cash from financing activities−1.3−0.1−12−2.8−0.3−8.0−7.653−1.8−4.9
Exchange-rate effect on cash———————0.31.8−1.6
Change in cash4.5−0.2−0.2−3.3−0.5−0.00.22.40.1−1.1
Report10-K10-K10-K10-K10-K10-K10-K/A10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Harvard Bioscience, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Instruments, Equipment, Software, and Accessories$78 M90%
  • Service, Maintenance, and Warranty Contracts$8 M9.6%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Harvard Bioscience, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Harvard Bioscience, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office$39 M45%
🇨🇳 China$11 M13%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Harvard Bioscience, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$905 K
John D. Duke
Other top executives, average
$344 K
the CEO earned 2.6× this
$100 invested is now
$10
Harvard Bioscience, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025John D. Duke$905 K$2.3 M$344 K$10
2024John D. Duke$2.3 M−$2.0 M$603 K$30
2023John D. Duke$2.4 M$7.2 M$571 K$76

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Harvard Bioscience, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Restructuring 1 · Directors and officers 9 · Material agreement 2 · Agreement ended 1 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 8

Harvard Bioscience, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Restructuring8-K
Bylaws or fiscal year changed8-K
Directors and officersMaterial agreementAgreement endedNew debt8-K
Results announced8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Directors and officers8-K
Delisting notice8-K/A
Delisting notice8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Government contracts: Harvard Bioscience, Inc.#

$1.6 M in federal contracts in fiscal 2026, mostly from Department of Defense and Department of Health and Human Services.

Contracts, FY2026
$1.6 M
#500 among companies on value.today
Grants, FY2026
—
FY2027 to date
—
contracts and grants
Since FY2008
$24.0 M
contracts and grants
  • Department of Defense$1.2 M
  • Department of Health and Human Services$233 K
  • Department of Veterans Affairs$180 K
Harvard Bioscience, Inc.: federal obligations by fiscal year
Fiscal yearContractsGrants
FY2026$1.6 M—
FY2025$1.6 M—
FY2024$1.9 M—
FY2023$1.8 M—
FY2022$1.1 M—
FY2021$1.6 M—
FY2020$1.8 M—
FY2019$3.1 M—
FY2018$2.4 M—
FY2017$2.5 M—
FY2016$1.1 M—
FY2015$1.1 M—
FY2014$404 K—
FY2013$342 K—
FY2012$140 K—
FY2011$363 K—
FY2010$249 K$421 K
FY2009$168 K$363 K
FY2008$133 K—

Source: USAspending.gov. Obligations are binding promises to pay, not payments, and can be negative when an award is cut. Counted under Harvard Bioscience, Inc.: HARVARD BIOSCIENCE INC (UEI CS6JFXF1C373)

H-1B hiring at Harvard Bioscience, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $141 K a year.

Certified, FY2026
1
#1,923 among companies on value.today
Worker positions
1
Median wage offered
$141 K
a year, full-time
Applications filed
1
Harvard Bioscience, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Engineering Manager, Firmware & Software TeamInformation Technology Project Managers1$141 K

Where: Holliston, MA 1

Harvard Bioscience, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$141 K1
FY202533$82 K3
FY202444$77 K4
FY202344$89 K4
FY202244$83 K4
FY202133$80 K3
FY202033$84 K3

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Harvard Bioscience Inc.

Layoffs at Harvard Bioscience, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2005–2026
Latest
—
2026-01-23
Harvard Bioscience, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
2019············—
2015············—
2013············—
2008············—
Harvard Bioscience, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling
13% of workforceRestructuring planSEC 8-K“The Company committed to the realignment plan on December 3, 2013, which will include reducing its workforce by approximately 13 percent by eliminating certain operational redundan…”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Harvard Bioscience, Inc. compares in Medical Instruments

  • Market cap$38 M · higher than 7% of 116
  • Revenue$87 M · higher than 18% of 120
  • Net margin-13.2% · higher than 12% of 114
  • Revenue growth-8.1% · higher than 8% of 49
  • Price / sales0.4× · lower than 98% of 85
  • Price / book2.7× · lower than 59% of 84
  • FCF yield14.5% · highest of 39

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Harvard Bioscience, Inc.🇺🇸$38 M—-13.2%-8.1%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Harvard Bioscience, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Harvard Bioscience, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Harvard Bioscience, Inc.? Suggest a correction